PYC Therapeutics Ltd - Asset Resilience Ratio
PYC Therapeutics Ltd (PYC) has an Asset Resilience Ratio of 83.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how PYC Therapeutics Ltd's Asset Resilience Ratio has changed over time. Check PYC Therapeutics Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down PYC Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PYC stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$153.05 Million | 83.51% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$153.05 Million | 83.51% |
Asset Resilience Insights
- Very High Liquidity: PYC Therapeutics Ltd maintains exceptional liquid asset reserves at 83.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
PYC Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare PYC Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for PYC Therapeutics Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for PYC Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 83.51% | AU$153.05 Million ≈ $108.29 Million |
AU$183.28 Million ≈ $129.68 Million |
+10.21pp |
| 2024-06-30 | 73.30% | AU$66.87 Million ≈ $47.32 Million |
AU$91.24 Million ≈ $64.56 Million |
+31.40pp |
| 2023-06-30 | 41.90% | AU$15.57 Million ≈ $11.02 Million |
AU$37.17 Million ≈ $26.30 Million |
-22.29pp |
| 2022-06-30 | 64.19% | AU$29.11 Million ≈ $20.60 Million |
AU$45.35 Million ≈ $32.09 Million |
-24.70pp |
| 2021-06-30 | 88.89% | AU$51.50 Million ≈ $36.44 Million |
AU$57.94 Million ≈ $41.00 Million |
+8.28pp |
| 2020-06-30 | 80.61% | AU$25.43 Million ≈ $17.99 Million |
AU$31.55 Million ≈ $22.32 Million |
-11.45pp |
| 2018-06-30 | 92.05% | AU$3.15 Million ≈ $2.23 Million |
AU$3.42 Million ≈ $2.42 Million |
-4.00pp |
| 2017-06-30 | 96.05% | AU$9.94 Million ≈ $7.03 Million |
AU$10.35 Million ≈ $7.32 Million |
-- |
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more